Interactions of poly(lactic acid) and poly(lactic acid-co-ethylene oxide) nanoparticles with the plasma factors of the coagulation system.
When surfactant-stabilized biodegradable poly(lactic acid) (PLA) particles are injected into rats, the rate of clearance from blood is fast. The rate can be strongly reduced by using particles made from diblock copolymers of PLA and poly(ethylene oxide) (PLA-PEO), resulting in an increased duration of contact with the components of the coagulation system. Thus, possible adverse effects such as activation of the coagulation cascade could occur. In this paper, the interactions of surfactant-stabilized PLA and PLA-PEO nanoparticle suspensions with the plasma factors of the coagulation system are presented. PLA suspensions stabilized by sodium cholate (PLA-Ch) interact with thrombin, factor V and calcium ions. Formation of complexes and aggregates is induced by addition of calcium ions to PLA-Ch suspensions in the presence or in the absence of plasma. On the contrary, PLA-PEO suspensions are remarkably inert towards the coagulation factors and calcium ions, even when cholate is present. Steric repulsion owing to the high surface density of PEO is sufficient to avoid strong interations with the proteins and formation of aggregates between particles.
Sahli
H
H
Laboratoire de Biomatérlaux et Polyméres, CNRS URA 1218 Physico-Chimie, Université Paris-Sud, Chatenay-Malabry, France.
Tapon-Bretaudière
J
J
Fischer
A M
AM
Sternberg
C
C
Spenlehauer
G
G
Verrecchia
T
T
Labarre
D
D
D001777:Blood Coagulation / Q000187:drug effects*; D001779:Blood Coagulation Factors / Q000187:drug effects* / Q000378:metabolism; D001798:Blood Proteins / Q000187:drug effects / Q000378:metabolism; D002118:Calcium / Q000097:blood; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D006801:Humans; D019344:Lactic Acid / Q000494:pharmacology*; D010316:Particle Size; D010743:Phospholipids / Q000097:blood; D011091:Polyesters; D011092:Polyethylene Glycols / Q000494:pharmacology*; D011108:Polymers / Q000494:pharmacology*; D013535:Suspensions; D013917:Thrombin / Q000187:drug effects / Q000378:metabolism
D001779:Blood Coagulation Factors; D001798:Blood Proteins; D010743:Phospholipids; D011091:Polyesters; D011108:Polymers; D013535:Suspensions; D019344:Lactic Acid; D011092:Polyethylene Glycols; C033616:poly(lactide); D013917:Thrombin; D002118:Calcium